Literature DB >> 14751510

PARP-1, PARP-2, and the cellular response to low doses of ionizing radiation.

Anthony Chalmers1, Peter Johnston, Mick Woodcock, Michael Joiner, Brian Marples.   

Abstract

PURPOSE: Poly(ADP-ribose) polymerase-1 (PARP-1) is rapidly and directly activated by single-strand breaks and is required for efficient base excision repair. These properties indicate that inhibition of PARP-1 might enhance the cellular response to low doses of radiation. We tested the effect of chemical inhibition of PARP-1 on low-dose clonogenic survival in a number of cell lines and the low-dose radiation response of a PARP-1 knockout murine cell line. METHODS AND MATERIALS: Clonogenic cell survival of V79-379A and CHO-K1 hamster fibroblasts, T98G and U373-MG human glioma cells, and 3T3 mouse embryo fibroblast PARP-1 knockout cells was measured using a precise flow cytometry-based plating assay. Chemical inhibitors of PARP enzymes were tested for their effect on clonogenic survival after a range of ionizing radiation doses.
RESULTS: Chemical inhibition of PARP activity induced marked radiosensitization of V79, CHO, and exponentially growing T98G cells in the 0.05-0.3-Gy range. This effect was not seen in U373 cells or in confluent T98G populations. Low-dose radiosensitization was not apparent in PARP-1 knockout cells.
CONCLUSION: Low-dose radiosensitization of actively dividing tumor cells by PARP-1 inhibitors suggests that they may have a role in enhancing the efficacy of ultrafractionated or low-dose-rate radiotherapy regimens. We hypothesize that PARP-2 compensates for the absence of PARP-1 in the knockout cell line.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14751510     DOI: 10.1016/j.ijrobp.2003.09.053

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  36 in total

1.  The potential for poly (ADP-ribose) polymerase inhibitors in cancer therapy.

Authors:  M Javle; N J Curtin
Journal:  Ther Adv Med Oncol       Date:  2011-11       Impact factor: 8.168

Review 2.  Hypersensitivity phenotypes associated with genetic and synthetic inhibitor-induced base excision repair deficiency.

Authors:  Julie K Horton; Samuel H Wilson
Journal:  DNA Repair (Amst)       Date:  2006-11-20

3.  Recent reports on the effect of low doses of ionizing radiation and its dose-effect relationship.

Authors:  M Tubiana; A Aurengo; D Averbeck; R Masse
Journal:  Radiat Environ Biophys       Date:  2006-02-09       Impact factor: 1.925

4.  The linear no-threshold relationship is inconsistent with radiation biologic and experimental data.

Authors:  Maurice Tubiana; Ludwig E Feinendegen; Chichuan Yang; Joseph M Kaminski
Journal:  Radiology       Date:  2009-04       Impact factor: 11.105

5.  Metabolic remodeling of malignant gliomas for enhanced sensitization during radiotherapy: an in vitro study.

Authors:  Chaim B Colen; Navid Seraji-Bozorgzad; Brian Marples; Matthew P Galloway; Andrew E Sloan; Saroj P Mathupala
Journal:  Neurosurgery       Date:  2006-12       Impact factor: 4.654

6.  Therapeutic targeting of constitutive PARP activation compromises stem cell phenotype and survival of glioblastoma-initiating cells.

Authors:  M Venere; P Hamerlik; Q Wu; R D Rasmussen; L A Song; A Vasanji; N Tenley; W A Flavahan; A B Hjelmeland; J Bartek; J N Rich
Journal:  Cell Death Differ       Date:  2013-10-11       Impact factor: 15.828

7.  MK-4827, a PARP-1/-2 inhibitor, strongly enhances response of human lung and breast cancer xenografts to radiation.

Authors:  Li Wang; Kathy A Mason; K Kian Ang; Thomas Buchholz; David Valdecanas; Anjili Mathur; Carolyn Buser-Doepner; Carlo Toniatti; Luka Milas
Journal:  Invest New Drugs       Date:  2011-11-30       Impact factor: 3.850

8.  A phase I trial of veliparib (ABT-888) and temozolomide in children with recurrent CNS tumors: a pediatric brain tumor consortium report.

Authors:  Jack M Su; Patrick Thompson; Adekunle Adesina; Xiao-Nan Li; Lindsay Kilburn; Arzu Onar-Thomas; Mehmet Kocak; Brenda Chyla; Evelyn McKeegan; Katherine E Warren; Stewart Goldman; Ian F Pollack; Maryam Fouladi; Alice Chen; Vincent Giranda; James Boyett; Larry Kun; Susan M Blaney
Journal:  Neuro Oncol       Date:  2014-06-07       Impact factor: 12.300

9.  The DNA-damage response: new molecular insights and new approaches to cancer therapy.

Authors:  Stephen P Jackson
Journal:  Biochem Soc Trans       Date:  2009-06       Impact factor: 5.407

Review 10.  PARP inhibitors: mechanism of action and their potential role in the prevention and treatment of cancer.

Authors:  Bristi Basu; Shahneen K Sandhu; Johann S de Bono
Journal:  Drugs       Date:  2012-08-20       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.